New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

2

Biogen Bumps Up Diversity for Post-Marketing Aduhelm Trial

While the Centers for Medicare & Medicaid Services undergoes the comment period on its national coverage decision for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab), Biogen and its partner company Eisai released additional details about the Phase IV post-marketing study of the drug.

5

Nonagen Bioscience looks to Peregrine Market Access to lead the commercialization of innovative bladder cancer diagnostic test

Peregrine Market Access, a leading life science commercialization partner, was selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria. The breakthrough bladder cancer diagnostic test Oncuria is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the U.S. launch of Oncuria.

Charles Joel Rosser

“After an extensive search for the right commer

6

Pfizer Elbows in to Vaccine Data Rollout, Janssen Fights Drug Lawsuit

After a U.S. District Court judge ruled that the U.S. Food and Drug Administration must begin disclosing data surrounding the approval of COVID-19 vaccines within a span of eight months, Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.

7

Studies Forge On as Omicron Surges and More COVID-19 News

In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding: thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy. More studies are still being run, especially in light of the Omicron surge and the virus’ ability to evolve.

9

Early research suggests Merck cancer drug may target dormant HIV

Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.

10

Most U.S. local governments opt to join $26 billion opioid settlement

U.S. cities and counties have embraced a proposed settlement worth up to $26 billion resolving lawsuits alleging three large drug distributors and drugmaker Johnson & Johnson fueled the U.S. opioid epidemic, lawyers behind the deal said on January 26, increasing the odds that it will move forward.